Ryvu Therapeutics among the founding members of 30% Club Poland

Krakow, Poland – June 10, 2021 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced joining 30% Club Poland.

The 30% Club, a global initiative promoting the business aspect of diversity has launched yesterday in Poland. Ryvu Therapeutics is among the first members to join the campaign in Poland. Just like the Founders of the Club, at Ryvu we strongly believe that gender diversity is an important part of the broader issue of diversity in governance.

Diversity is the clue to allowing for a wider range of experience, knowledge, and competence at the management levels, which in turn leads to better decision making and a stronger corporate culture, benefiting not only the company itself but also the economy and society.

The goal of 30% Club Poland is to increase the representation of women to at least 30% of management and supervisory boards combined in 140 of the largest Polish listed companies by 2030. Read more about this great initiative at: https://30percentclub.org